Bioniche Inc., Seikagaku Corp. deal

Under a previously announced agreement, Seikagaku provided an initial installment of C$500,000 (US$362,500) to BNC toward the development of BNC's Cystistat hyaluronate-based product to treat interstitial cystitis, a bladder condition (see BioCentury Nov. 20, 1995). ...